Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system.
By C. Balch, S. Soong, J. Gershenwald, John F. Thompson, D. Reintgen, N. Cascinelli, M. Urist, K. McMasters, M. Ross, J. Kirkwood and 9 more. Journal of Clinical Oncology, 2001
2,382 citations recorded by the source corpus.
Subfields: Epidemiology, Molecular Biology, Oncology
View Paper: https://www.semanticscholar.org/paper/35b4d1665e37a167bff0a6ae75d08a148b1c838d
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Epidemiology
In Molecular Biology
In Oncology
Citations in the corpus
- Final version of 2009 AJCC melanoma staging and classification. (2009, methodology): “© 2009 by American Society of Clinical Oncology INTRODUCTION The current melanoma staging system was substantially revised in 2001 for the sixth edition of the Cancer Staging Manual, on the basis of an analysis of 17,600 patients in the American Joint Committee on Cancer (AJCC) Melanoma Staging Data”
- Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma. (2012, background): “pendent principally on tumor thickness and to a lesser extent on other features of the primary tumor, such as mitotic rate, ulcerative state, and anatomic site, as well as patient characteristics, such as age and sex.(3,4) In recent times, additional prognostic information has been obtained by senti”
- Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. (2001, methodology): “0 mm thick, (2) absence of ulceration, and (3) depth of invasion limited to level II or level III.”
- NRAS Mutation Status is an Independent Prognostic Factor in Metastatic Melanoma (2011, neutral): “6 [0-517] 27.”
- Early diagnosis of cutaneous melanoma: revisiting the ABCD criteria. (2004, background): “Tumor thickness, a measurement of tumor invasion into the dermis, is a powerful prognostic factor and a key component for the staging of localized melanoma.(29) In published data from other groups, small-diameter melanoma tumor thicknesses ranged from 0.”
- Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis (2006, background): “According to the American Joint Committee on Cancer, patients with advanced metastatic melanoma (stage IV) have a 5-year survival rate of only 2% (Balch et al, 2001).”